Business Wire

MN-NCIPHER-SECURITY

7.4.2020 09:12:10 CEST | Business Wire | Press release

Share
Customer Personal Information Is the Number One Data Protection Priority – nCipher 2020 Global Encryption Trends Study

As organizations accelerate digital initiatives such as cloud and the internet of things (IoT), and data volumes and types continue to rise, IT professionals cite protection of customer personal information as their number one priority, according to the 2020 Global Encryption Trends Study from the Ponemon Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005297/en/

The Ponemon Institute has collaborated with nCipher Security , an Entrust Datacard company and world leader in hardware security modules (HSMs), on this multinational survey of how and why organizations deploy encryption, now in its fifteenth year.

Threats, drivers and priorities

For the first time, protecting consumer personal information is the top driver for deploying encryption (54% of respondents), outranking compliance, which ranked fourth (47%). Traditionally compliance with regulations was the top driver for deploying encryption, but has dropped in priority since 2017, indicating that encryption is transitioning from a requirement to a proactive choice to safeguard critical information.

Employee mistakes continue to be the biggest threat to sensitive data (54%) and significantly outweigh concerns over attacks by hackers (29%), or malicious insiders (20%). In contrast, the least significant threats cited include government eavesdropping (11%) and lawful data requests (12%).

Data discovery the number one challenge

With the proliferation of data from digital initiatives, cloud use, mobility, IoT devices and the advent of 5G networks, data discovery continues to be the biggest challenge in planning and executing a data encryption strategy, with 67% of respondents citing this as their top concern. And that is likely to increase, with a pandemic-driven surge in employees working remotely, using data at home, creating extra copies on personal devices and cloud storage.

Blockchain, quantum and adoption of new encryption technologies

The study indicates that 48% of organizations have adopted encryption strategies across their enterprises, up from 45% in 2019. With encryption deployment steadily growing, how are organizations looking ahead? In the near term, 60% of organizations plan to use blockchain, with cryptocurrency/wallets, asset transactions, identity, supply chain and smart contracts cited at the top use cases.

Other much-hyped technologies are not on IT organizations’ near-term radar. Most IT professionals see the mainstream adoption of multi-party computation at least five years away, with mainstream adoption of homomorphic encryption more than six years away, and quantum resistant algorithms over eight years out.

Trust, integrity, control

The use of hardware security modules (HSMs) continues to grow, with 48% of respondents deploying HSMs to provide a hardened, tamper-resistant environment with higher levels of trust, integrity and control for both data and applications. Organizations in Germany, the United States and Middle East are more likely to deploy HSMs, with Australia, Germany and the United States most likely to assign importance to HSMs as part of their organization’s encryption or key management activities.

HSM usage is no longer limited to traditional use cases such as public key infrastructure (PKI), databases, application and network encryption (TLS/SSL). The demand for trusted encryption for new digital initiatives has driven significant HSM growth for big data encryption (up 17%) code signing (up 12%), IoT root of trust (up 10%) and document signing (up 7%). Additionally, 35% of respondents report using HSMs to secure access to public cloud applications.

The race to the cloud

Eighty-three percent of respondents report transferring sensitive data to the cloud, or planning to do so within the next 12 to 24 months, with organizations in the United States, Brazil, Germany, India and South Korea doing so most frequently.

In the next 12 months, respondents predict a significant increase in the ownership and operation of HSMs to generate and manage Bring Your Own Key (BYOK), and integration with a Cloud Access Security Broker (CASB) to manage keys and cryptographic operations. The survey found that the most important cloud encryption features are:

  • support for Key Management Interoperability Protocol (KMIP) (67%)
  • security information and event management (SIEM) integration (62%)
  • granular access controls (60%)
  • key usage audit logs (55%), and
  • privileged user access controls (50%).

“Consumers expect brands to keep their data safe from breaches and have their best interests at heart. The survey found that IT leaders are taking this seriously, with protection of consumer data cited as the top driver of encryption growth for the first time,” says Dr Larry Ponemon, chairman and founder of Ponemon Institute. “Encryption use is at an all-time high with 48% of respondents this year saying their organization has an overall encryption plan applied consistently across the entire enterprise, and a further 39% having a limited plan or strategy applied to certain application and data types.”

“As the world goes digital, the impact of the global pandemic highlights how security and identity have become critical for organizations and individuals both at work and at home,” says John Grimm vice president of strategy at nCipher Security. “Organizations are under relentless pressure to deliver high security and seamless access – protecting their customer data, business critical information and applications while ensuring business continuity. nCipher empowers customers by providing a high assurance security foundation that ensures the integrity and trustworthiness of their data, applications and intellectual property.”

Other key trends include:

  • The highest prevalence of organizations with an enterprise encryption strategy is in Germany (66%) followed by the United States (66%), Sweden (62%), Hong Kong (60%), Netherlands (56%) and the United Kingdom (54%).
  • Payment-related data (54% of respondents) and financial records (54% of respondents) are most likely to be encrypted.
  • The least likely data type to be encrypted is health-related information (25% of respondents), a surprising result given the sensitivity of this information and recent high-profile healthcare data breaches.
  • The industries seeing the most significant increase in extensive encryption usage are manufacturing (49%), hospitality (44%) and consumer products (43%).

Download the 2020 Global Encryption Trends Study here .

2020 Global Encryption Trends Study methodology

The 2020 Global Encryption Trends Study, based on research by the Ponemon Institute, captures how organizations around the world are dealing with compliance, increased threats, and the implementation of encryption to protect their business critical information and applications. 6,457 IT professionals were surveyed across multiple industry sectors in 17 countries/regions: Australia, Brazil, France, Germany, India, Japan, Hong Kong, Mexico, the Middle East (which is a combination of respondents located in Saudi Arabia and the United Arab Emirates), the Russian Federation, Southeast Asia (Indonesia, Malaysia, Philippines, Thailand, and Vietnam), South Korea, Taiwan, the United Kingdom, the United States and two new regions for the first time, Netherlands and Sweden.

About nCipher Security

nCipher Security, an Entrust Datacard company, is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com

Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye